Clinical Observation
October 25, 1999

Investigations of Possible Failures of Postexposure Prophylaxis Following Occupational Exposures to Human Immunodeficiency Virus

Author Affiliations

From the HIV Infections Branch, Hospital Infections Program (Drs Jochimsen and Cardo) and Division of AIDS, STD, and TB Laboratory Research (Drs Luo and Respess and Mr Schable), National Center for Infectious Diseases, Centers for Disease Control and Prevention, and Georgia Department of Human Resources (Dr Beltrami), Atlanta.


Copyright 1999 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.1999

Arch Intern Med. 1999;159(19):2361-2363. doi:10.1001/archinte.159.19.2361

Information suggesting that zidovudine postexposure prophylaxis (PEP) reduces the risk of human immunodeficiency virus (HIV) transmission after occupational exposure to HIV-infected blood prompted the US Public Health Service to provide guidelines for the use of combination drug therapy for chemoprophylaxis after certain occupational exposures to HIV.1,2 Many health care workers (HCWs) worldwide may take PEP following occupational exposures to HIV.

First Page Preview View Large
First page PDF preview
First page PDF preview